Logo image of ESF0.DE

EUROFINS SCIENTIFIC (ESF0.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:ESF0 - FR0014000MR3 - Common Stock

58.06 EUR
0 (0%)
Last: 11/24/2025, 7:00:00 PM
Fundamental Rating

6

ESF0 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 19 industry peers in the Life Sciences Tools & Services industry. ESF0 has only an average score on both its financial health and profitability. ESF0 is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, ESF0 could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

ESF0 had positive earnings in the past year.
In the past year ESF0 had a positive cash flow from operations.
Each year in the past 5 years ESF0 has been profitable.
Each year in the past 5 years ESF0 had a positive operating cash flow.
ESF0.DE Yearly Net Income VS EBIT VS OCF VS FCFESF0.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

ESF0 has a Return On Assets (3.54%) which is comparable to the rest of the industry.
ESF0's Return On Equity of 8.09% is in line compared to the rest of the industry. ESF0 outperforms 57.89% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.79%, ESF0 belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ESF0 is in line with the industry average of 7.47%.
The 3 year average ROIC (8.70%) for ESF0 is below the current ROIC(9.79%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.54%
ROE 8.09%
ROIC 9.79%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ESF0.DE Yearly ROA, ROE, ROICESF0.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

ESF0 has a Profit Margin (5.44%) which is comparable to the rest of the industry.
In the last couple of years the Profit Margin of ESF0 has grown nicely.
ESF0's Operating Margin of 15.59% is in line compared to the rest of the industry. ESF0 outperforms 57.89% of its industry peers.
ESF0's Operating Margin has improved in the last couple of years.
The Gross Margin of ESF0 (23.29%) is worse than 78.95% of its industry peers.
In the last couple of years the Gross Margin of ESF0 has grown nicely.
Industry RankSector Rank
OM 15.59%
PM (TTM) 5.44%
GM 23.29%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
ESF0.DE Yearly Profit, Operating, Gross MarginsESF0.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ESF0 is creating some value.
Compared to 1 year ago, ESF0 has less shares outstanding
The number of shares outstanding for ESF0 has been increased compared to 5 years ago.
The debt/assets ratio for ESF0 has been reduced compared to a year ago.
ESF0.DE Yearly Shares OutstandingESF0.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ESF0.DE Yearly Total Debt VS Total AssetsESF0.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

An Altman-Z score of 2.63 indicates that ESF0 is not a great score, but indicates only limited risk for bankruptcy at the moment.
ESF0 has a Altman-Z score (2.63) which is in line with its industry peers.
The Debt to FCF ratio of ESF0 is 5.25, which is a neutral value as it means it would take ESF0, 5.25 years of fcf income to pay off all of its debts.
ESF0 has a better Debt to FCF ratio (5.25) than 73.68% of its industry peers.
A Debt/Equity ratio of 0.77 indicates that ESF0 is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.77, ESF0 is doing worse than 63.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.25
Altman-Z 2.63
ROIC/WACC1.25
WACC7.83%
ESF0.DE Yearly LT Debt VS Equity VS FCFESF0.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

ESF0 has a Current Ratio of 1.26. This is a normal value and indicates that ESF0 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.26, ESF0 is in line with its industry, outperforming 47.37% of the companies in the same industry.
A Quick Ratio of 1.19 indicates that ESF0 should not have too much problems paying its short term obligations.
The Quick ratio of ESF0 (1.19) is better than 89.47% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.19
ESF0.DE Yearly Current Assets VS Current LiabilitesESF0.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

5

3. Growth

3.1 Past

ESF0 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.50%, which is quite good.
Measured over the past years, ESF0 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.34% on average per year.
ESF0 shows a small growth in Revenue. In the last year, the Revenue has grown by 2.53%.
The Revenue has been growing by 8.78% on average over the past years. This is quite good.
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%

3.2 Future

The Earnings Per Share is expected to grow by 15.60% on average over the next years. This is quite good.
ESF0 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.38% yearly.
EPS Next Y14.65%
EPS Next 2Y13.56%
EPS Next 3Y14%
EPS Next 5Y15.6%
Revenue Next Year5.1%
Revenue Next 2Y5.44%
Revenue Next 3Y5.91%
Revenue Next 5Y7.38%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ESF0.DE Yearly Revenue VS EstimatesESF0.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B 10B
ESF0.DE Yearly EPS VS EstimatesESF0.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6

7

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 16.13, the valuation of ESF0 can be described as correct.
Based on the Price/Earnings ratio, ESF0 is valued cheaply inside the industry as 89.47% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ESF0 to the average of the S&P500 Index (25.98), we can say ESF0 is valued slightly cheaper.
A Price/Forward Earnings ratio of 14.58 indicates a correct valuation of ESF0.
Based on the Price/Forward Earnings ratio, ESF0 is valued cheaply inside the industry as 89.47% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.79, ESF0 is valued rather cheaply.
Industry RankSector Rank
PE 16.13
Fwd PE 14.58
ESF0.DE Price Earnings VS Forward Price EarningsESF0.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ESF0 indicates a rather cheap valuation: ESF0 is cheaper than 89.47% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ESF0 is valued cheaply inside the industry as 94.74% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.49
EV/EBITDA 8.2
ESF0.DE Per share dataESF0.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

ESF0's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ESF0 has a very decent profitability rating, which may justify a higher PE ratio.
ESF0's earnings are expected to grow with 14.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.1
PEG (5Y)0.88
EPS Next 2Y13.56%
EPS Next 3Y14%

4

5. Dividend

5.1 Amount

ESF0 has a Yearly Dividend Yield of 1.05%.
ESF0's Dividend Yield is rather good when compared to the industry average which is at 0.73. ESF0 pays more dividend than 84.21% of the companies in the same industry.
With a Dividend Yield of 1.05, ESF0 pays less dividend than the S&P500 average, which is at 2.41.
Industry RankSector Rank
Dividend Yield 1.05%

5.2 History

The dividend of ESF0 is nicely growing with an annual growth rate of 16.51%!
Dividend Growth(5Y)16.51%
Div Incr Years1
Div Non Decr Years1
ESF0.DE Yearly Dividends per shareESF0.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

ESF0 pays out 54.91% of its income as dividend. This is a bit on the high side, but may be sustainable.
ESF0's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP54.91%
EPS Next 2Y13.56%
EPS Next 3Y14%
ESF0.DE Yearly Income VS Free CF VS DividendESF0.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
ESF0.DE Dividend Payout.ESF0.DE Dividend Payout, showing the Payout Ratio.ESF0.DE Dividend Payout.PayoutRetained Earnings

EUROFINS SCIENTIFIC

FRA:ESF0 (11/24/2025, 7:00:00 PM)

58.06

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-21 2025-10-21
Earnings (Next)01-28 2026-01-28/amc
Inst Owners37.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap10.58B
Revenue(TTM)6.89B
Net Income(TTM)374.80M
Analysts69.47
Price Target64.73 (11.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.05%
Yearly Dividend0.52
Dividend Growth(5Y)16.51%
DP54.91%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.8%
PT rev (3m)1.24%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.09%
EPS NY rev (3m)1.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)-0.74%
Valuation
Industry RankSector Rank
PE 16.13
Fwd PE 14.58
P/S 1.53
P/FCF 13.49
P/OCF 8.04
P/B 2.28
P/tB N/A
EV/EBITDA 8.2
EPS(TTM)3.6
EY6.2%
EPS(NY)3.98
Fwd EY6.86%
FCF(TTM)4.3
FCFY7.41%
OCF(TTM)7.22
OCFY12.43%
SpS37.84
BVpS25.45
TBVpS-3.69
PEG (NY)1.1
PEG (5Y)0.88
Graham Number45.4
Profitability
Industry RankSector Rank
ROA 3.54%
ROE 8.09%
ROCE 12.64%
ROIC 9.79%
ROICexc 10.74%
ROICexgc 34.1%
OM 15.59%
PM (TTM) 5.44%
GM 23.29%
FCFM 11.37%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ROICexc(3y)9.52%
ROICexc(5y)11.6%
ROICexgc(3y)31.02%
ROICexgc(5y)39.55%
ROCE(3y)11.31%
ROCE(5y)13.7%
ROICexgc growth 3Y-18.17%
ROICexgc growth 5Y3.78%
ROICexc growth 3Y-15.5%
ROICexc growth 5Y6.63%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
F-Score7
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.25
Debt/EBITDA 2.1
Cap/Depr 84.94%
Cap/Sales 7.7%
Interest Coverage 9.93
Cash Conversion 77.37%
Profit Quality 209.21%
Current Ratio 1.26
Quick Ratio 1.19
Altman-Z 2.63
F-Score7
WACC7.83%
ROIC/WACC1.25
Cap/Depr(3y)89.21%
Cap/Depr(5y)85.64%
Cap/Sales(3y)8.63%
Cap/Sales(5y)7.99%
Profit Quality(3y)162.79%
Profit Quality(5y)158.88%
High Growth Momentum
Growth
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
EPS Next Y14.65%
EPS Next 2Y13.56%
EPS Next 3Y14%
EPS Next 5Y15.6%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%
Revenue Next Year5.1%
Revenue Next 2Y5.44%
Revenue Next 3Y5.91%
Revenue Next 5Y7.38%
EBIT growth 1Y14.03%
EBIT growth 3Y-10.93%
EBIT growth 5Y12.66%
EBIT Next Year86.11%
EBIT Next 3Y30.34%
EBIT Next 5Y22.43%
FCF growth 1Y113.13%
FCF growth 3Y-7.69%
FCF growth 5Y25.62%
OCF growth 1Y31.31%
OCF growth 3Y-4.44%
OCF growth 5Y14.24%

EUROFINS SCIENTIFIC / ESF0.DE FAQ

Can you provide the ChartMill fundamental rating for EUROFINS SCIENTIFIC?

ChartMill assigns a fundamental rating of 6 / 10 to ESF0.DE.


Can you provide the valuation status for EUROFINS SCIENTIFIC?

ChartMill assigns a valuation rating of 7 / 10 to EUROFINS SCIENTIFIC (ESF0.DE). This can be considered as Undervalued.


What is the profitability of ESF0 stock?

EUROFINS SCIENTIFIC (ESF0.DE) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for ESF0 stock?

The Earnings per Share (EPS) of EUROFINS SCIENTIFIC (ESF0.DE) is expected to grow by 14.65% in the next year.


Can you provide the dividend sustainability for ESF0 stock?

The dividend rating of EUROFINS SCIENTIFIC (ESF0.DE) is 4 / 10 and the dividend payout ratio is 54.91%.